Our focus

Our expertise

Fresenius Kabi has a long history of devotion towards providing high-quality, competitive and affordable products and services. Our offerings deliver life-changing medicines for more patients with chronic and acute diseases, with expertise in clinical nutrition, infusion therapies, IV generic drugs, infusion and transfusion medical devices and quality services. We make a difference where it counts by powering our operations end-to-end, from R&D expertise through to optimized manufacturing and supply capabilities. This means we can help unlock access to more medicines for more patients at the right price.

Fresenius Kabi has a heritage of expertise that allows us to:

  • Provide high-quality, affordable therapies for the care of our critically and chronically ill patients
  • Develop, manufacture and commercialize biosimilar medicines
  • Supply more essential medicines and technologies to help those who care for patients
  • Be members of Medicines for Europe, which represents the generic, biosimilar and value-added medicines industries
  • Be members of the Association for Accessible Medicines in the US
  • Be members of the Biosimilars Forum, a non-profit organization to advance biosimilars in the US

Fresenius Kabi biosimilars specialize in:

  • Treating diseases of the autoimmune system and oncology
  • Developing and commercializing high-standard biosimilars, meeting the high standards of EU and US regulators
  • Focusing on our biosimilars’ unique ability to improve access for patients, allowing them more affordable treatment
  • Developing a strong pipeline of biosimilar molecules to be launched soon
  • Bringing patient insights and understanding to life, to go beyond in our level of care
  • Encouraging innovation in the biologics field

Biosimilars by Fresenius Kabi

Read our brochure which explains how, as a global healthcare company specialising in life-improving medicines and technologies for infusion, transfusion and clinical nutrition, we leverage our expertise in manufacturing and biotechnology to develop affordable biosimilar products with the potential to improve the lives of patients worldwide.

IV, intravenous